MSB 8.37% $1.15 mesoblast limited

Keep Calm - it aint that bad!, page-52

  1. 693 Posts.
    lightbulb Created with Sketch. 266
    Morform

    Yep - exciting stuff!

    But the Calimmune technology acquired by CSL is totally different to the MSB technology, unfortunately.

    It is based around autologous hematopoietic stem cells - the blood forming cells - not the mesenchymal cells. And it works by taking the cells, genetically engineering them, and putting them back into the patient where they engraft and replace the patient's defective blood cells (MSB's cells do not engraft).

    Their patents are not around the stem cells (this technology has been used for decades) - CSL has invested to access the genetic engineering technology. So the excitement is around the GE bit, not the stem cell bit.

    There is, of course, a connection - a common complication of allogeneic hematopoietic stem cell therapy is GvHD, which we know about.
    Last edited by Techinvestor: 30/08/17
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.15
Change
-0.105(8.37%)
Mkt cap ! $1.313B
Open High Low Value Volume
$1.22 $1.23 $1.14 $9.583M 8.106M

Buyers (Bids)

No. Vol. Price($)
1 10000 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 25000 2
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.